Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib with Azacitidine and Chidamide in PTCL
NCT07081607Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Ruijin Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07081607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081607.